Can camlipixant improve quality of life of patients with refractory chronic cough?

Presented by

Dr Lorcan McGarvey, Queen’s University Belfast, UK

Conference

ATS 2023

Trial

Phase 2, SOOTHE

Doi
https://doi.org/10.55788/c30900fd

Both objective cough frequency and patient-reported cough severity improved significantly in patients with refractory chronic cough (RCC) if they were treated with camlipixant, results from the phase 2b SOOTHE trial demonstrated.

Camlipixant is a selective P2X3 receptor inhibitor that is being tested as a potential therapy for patients with RCC. The SOOTHE trial (NCT04678206) randomised 249 patients to placebo (n=63) or to 1 of 3 dose groups of camlipixant; 12.5 mg, twice daily; 50 mg, twice daily; or 200 mg, twice daily [1]. “The primary outcome of ‘change in objective cough frequency’ was presented at last year’s meeting,” said Dr Lorcan McGarvey (Queen’s University Belfast, UK) [2]. “However, we need to know whether the quality of life of patients with RCC improves if they are treated with camlipixant.” For this purpose, Dr McGarvey presented the outcomes of patient-reported cough severity, assessed by the cough severity visual analogue scale (VAS).

At day 15, all treatment groups demonstrated significant improvements in the cough severity VAS, with mean changes of -16.1 mm for the lowest dose group, -22.9 mm for the intermediate dose group, and -26.5 mm for the highest dose group, compared with a mean change of -3.7 mm for patients in the placebo group (P<0.001 for all). “The treatment effects appeared to become larger at Day 29,” added Dr McGarvey. At day 29 namely, 44% of the patients in the highest dose group achieved a response rate ≥30 mm on the cough severity VAS, implying that this agent may instigate a clinically meaningful improvement in quality of life in a significant proportion of patients.

In conclusion, the SOOTHE trial displayed that camlipixant may have the potential to improve the objective cough frequency and the quality of life of patients with RCC.

McGarvey L, et al. Response in patient-reported cough severity in SOOTHE, a phase 2b trial of camlipixant in refractory chronic cough. Session A99, ATS International Conference 2023, 19–24 May, Washington DC, USA.

Smith J, et al. Am J Respir Crit Care Med. 2022;205:A5778.

Medical Conferences

Can camlipixant improve quality of life of patients with refractory chronic cough?

Table of Contents: ATS 2023

Featured articles

TORREY trial: seralutinib associated with reduced pulmonary vascular resistance in PAH

Practice-changing results for ensifentrine in COPD

Asthma

Vitamin D for asthma protection: what is the optimal timing?

Remarkable results for novel biologic therapy for asthma

Success for fluticasone furoate plus vilanterol in uncontrolled asthma

COPD

Practice-changing results for ensifentrine in COPD

Alvelestat for AATD meets primary endpoints in phase 2 trial

Fewer exacerbations with dupilumab in COPD with type 2 inflammation

New AATD therapy may alleviate treatment burden for patients

Efficient detection of AECOPD with at-home vital signs monitoring

COVID-19

COVA trial: success for the investigational agent sarconeos in hospitalised COVID-19

Mitochondrial DNA levels predict COVID-19 severity

Other

Excellent results for C21 in idiopathic pulmonary fibrosis